Vanda Pharmaceuticals Inc.

VNDA21 Jan 2025
Healthcare
$4.42
+0.01 (+1.49%)
Lowest Today
$4.41
Highest Today
$4.47
Today’s Open
$4.42
Prev. Close
$4.36
52 Week High
$6.75
52 Week Low
$3.46
To Invest in Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.

Healthcare
VNDA21 Jan 2025
+0.01 (+1.49%)
1M
3M
6M
1Y
5Y
Low
$4.4
Day’s Range
High
$4.47
4.4
52 Week Low
$3.46
52-Week Range
52 Week High
$6.75
3.46
1 Day
-
1 Week
-3.52%
1 month return
-5.39%
3 month return
-7.39%
6 month return
-28.19%
1 Year return
+20%
3 Years return
-68.46%
5 Years return
-70.78%
10 Years return
-
Institutional Holdings
BlackRock Inc
14.74
Renaissance Technologies Corp
6.88
Vanguard Group Inc
6.23
TANG CAPITAL MANAGEMENT LLC
4.04
Dimensional Fund Advisors, Inc.
3.88
Vanguard Total Stock Mkt Idx Inv
2.99
Nantahala Capital Management, LLC
2.73

Market Status

Fundamentals
Market Cap
314.86 mln
PB Ratio
0.48
PE Ratio
0
Enterprise Value
-109.43 mln
Total Assets
648.44 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Organisation
Vanda Pharmaceuticals Inc.
Employees
203
Industry
Biotechnology
CEO
Dr. Mihael H. Polymeropoulos M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities